1274 related articles for article (PubMed ID: 17548134)
1. Immunogenicity and in vitro protective efficacy of a polyepitope Plasmodium falciparum candidate vaccine constructed by epitope shuffling.
Cai Q; Peng G; Bu L; Lin Y; Zhang L; Lustigmen S; Wang H
Vaccine; 2007 Jul; 25(28):5155-65. PubMed ID: 17548134
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of polyepitope libraries assembled by epitope shuffling: an approach to the development of chimeric gene vaccination against malaria.
Cai QL; Wei F; Lin YH; Shao DD; Wang H
Vaccine; 2004 Nov; 23(2):267-77. PubMed ID: 15531046
[TBL] [Abstract][Full Text] [Related]
4. Identification of minimal CD8+ and CD4+ T cell epitopes in the Plasmodium yoelii hepatocyte erythrocyte protein 17kDa.
Dobaño C; Doolan DL
Mol Immunol; 2007 Apr; 44(11):3037-48. PubMed ID: 17303242
[TBL] [Abstract][Full Text] [Related]
5. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of recombinant BCG-based vaccine expressing the 22 kDa of serine repeat antigen (SE22) of Plasmodium falciparum.
Teo WH; Nurul AA; Norazmi MN
Trop Biomed; 2012 Jun; 29(2):239-53. PubMed ID: 22735846
[TBL] [Abstract][Full Text] [Related]
7. Plasmodium falciparum: an epitope within a highly conserved region of the 47-kDa amino-terminal domain of the serine repeat antigen is a target of parasite-inhibitory antibodies.
Fox BA; Xing-Li P; Suzue K; Horii T; Bzik DJ
Exp Parasitol; 1997 Feb; 85(2):121-34. PubMed ID: 9030663
[TBL] [Abstract][Full Text] [Related]
8. Antibodies and reactive T cells against the malaria heat-shock protein Pf72/Hsp70-1 and derived peptides in individuals continuously exposed to Plasmodium falciparum.
Behr C; Sarthou JL; Rogier C; Trape JF; Dat MH; Michel JC; Aribot G; Dieye A; Claverie JM; Druihle P
J Immunol; 1992 Nov; 149(10):3321-30. PubMed ID: 1431109
[TBL] [Abstract][Full Text] [Related]
9. A recombinant multi-epitope, multi-stage malaria vaccine candidate expressed in Escherichia coli.
Li M; Bi H; Dong W; Xu W; Li Q; Li Y
Chin Med J (Engl); 1999 Aug; 112(8):691-7. PubMed ID: 11601273
[TBL] [Abstract][Full Text] [Related]
10. Binding of malaria T cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T cell epitope in the Plasmodium falciparum circumsporozoite protein.
Calvo-Calle JM; Hammer J; Sinigaglia F; Clavijo P; Moya-Castro ZR; Nardin EH
J Immunol; 1997 Aug; 159(3):1362-73. PubMed ID: 9233633
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Plasmodium vivax combination subunit vaccine formulated with human compatible adjuvants in mice.
Devi YS; Mukherjee P; Yazdani SS; Shakri AR; Mazumdar S; Pandey S; Chitnis CE; Chauhan VS
Vaccine; 2007 Jul; 25(28):5166-74. PubMed ID: 17544179
[TBL] [Abstract][Full Text] [Related]
12. Phase I dose escalation safety and immunogenicity trial of Plasmodium falciparum apical membrane protein (AMA-1) FMP2.1, adjuvanted with AS02A, in malaria-naïve adults at the Walter Reed Army Institute of Research.
Polhemus ME; Magill AJ; Cummings JF; Kester KE; Ockenhouse CF; Lanar DE; Dutta S; Barbosa A; Soisson L; Diggs CL; Robinson SA; Haynes JD; Stewart VA; Ware LA; Brando C; Krzych U; Bowden RA; Cohen JD; Dubois MC; Ofori-Anyinam O; De-Kock E; Ballou WR; Heppner DG
Vaccine; 2007 May; 25(21):4203-12. PubMed ID: 17442466
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity and protective efficacy of Escherichia coli expressed Plasmodium falciparum merozoite surface protein-1(42) using human compatible adjuvants.
Sachdeva S; Mohmmed A; Dasaradhi PV; Crabb BS; Katyal A; Malhotra P; Chauhan VS
Vaccine; 2006 Mar; 24(12):2007-16. PubMed ID: 16377036
[TBL] [Abstract][Full Text] [Related]
14. Differential antibody responses to Plasmodium falciparum-derived B-cell epitopes induced by diepitope multiple antigen peptides (MAP) containing different T-cell epitopes.
Vasconcelos NM; Siddique AB; Ahlborg N; Berzins K
Vaccine; 2004 Dec; 23(3):343-52. PubMed ID: 15530679
[TBL] [Abstract][Full Text] [Related]
15. Tandem use of PCR and synthetic peptides to map helper T-cell epitopes on 27-kDa sexual stage antigen of Plasmodium falciparum.
Koski GK; Ploton IN; Viscidi R; Kumar N
Pept Res; 1996; 9(3):127-35. PubMed ID: 8875592
[TBL] [Abstract][Full Text] [Related]
16. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
17. Detection of CD4+CD45RO+ T lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites.
Bergmann ES; Ballou RW; Krzych U
Cell Immunol; 1997 Sep; 180(2):143-52. PubMed ID: 9341744
[TBL] [Abstract][Full Text] [Related]
18. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T helper, and cytotoxic T lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees.
BenMohamed L; Gras-Masse H; Tartar A; Daubersies P; Brahimi K; Bossus M; Thomas A; Druilhe P
Eur J Immunol; 1997 May; 27(5):1242-53. PubMed ID: 9174617
[TBL] [Abstract][Full Text] [Related]
19. Effects of the configuration of a multi-epitope chimeric malaria DNA vaccine on its antigenicity to mice.
Jiang Y; Lin C; Yin B; He X; Mao Y; Dong M; Xu P; Zhang L; Liu B; Wang H
Chin Med J (Engl); 1999 Aug; 112(8):686-90. PubMed ID: 11601272
[TBL] [Abstract][Full Text] [Related]
20. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
